Ken Griffin Aptinyx Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.23 - $0.34 $2,070 - $3,060
-9,000 Reduced 81.82%
2,000 $0
Q3 2022

Nov 14, 2022
SELL
$0.35 - $0.72 $6,965 - $14,328
-19,900 Reduced 64.4%
11,000 $4,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email